This study seeks to examine if there is any relationship between spironolactone use prescribed for acne vulgaris and depression, anxiety, and/or sexual function.
Study Type
OBSERVATIONAL
Online survey completion through Northwestern's REDCap
Northwestern University
Chicago, Illinois, United States
Percent correlation between spironolactone use for acne vulgaris and increased prevalence of depression.
Score for depression from subject reported Dermatology Life Quality Index (DLQI) survey
Time frame: one week
Percent correlation between spironolactone use for acne vulgaris and increased prevalence of anxiety.
Score for depression from subject reported Generalized Anxiety Disorder (GAD-7) survey
Time frame: two weeks
Percent correlation between spironolactone use for acne vulgaris and increased prevalence of sexual dysfunction.
Score for depression from subject reported Female Sexual Function Index (FSFI) survey.
Time frame: four weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.